Adaptimmune Therapeutics PLC — Investor Relations & Filings
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| SCHEDULE 13G Filing | 2026-02-17 | English | |
| Regulatory Filings 2025 | 2025-11-17 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| Regulatory Filings 2025 | 2025-11-13 | English | |
| 15-12G | 2025-11-13 | English | |
| S-8 POS | 2025-10-28 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
1 filing
| |||||
| 30972621 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
|
2025
14 filings
| |||||
| 12820260 | Regulatory Filings 2025 | 2025-11-17 | English | ||
| 12820261 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 12820262 | Regulatory Filings 2025 | 2025-11-13 | English | ||
| 12820263 | 15-12G | 2025-11-13 | English | ||
| 12820264 | S-8 POS | 2025-10-28 | English | ||
| 12820265 | S-8 POS | 2025-10-28 | English | ||
| 12820266 | S-8 POS | 2025-10-28 | English | ||
| 12820267 | POS AM | 2025-10-28 | English | ||
| 12820268 | FORM 25 | 2025-10-28 | English | ||
| 12820269 | 8-K | 2025-10-20 | English | ||
| 12820270 | OWNERSHIP DOCUMENT | 2025-10-09 | English | ||
| 12820271 | 8-K | 2025-09-26 | English | ||
| 12820272 | 8-K | 2025-09-12 | English | ||
| 12820273 | 8-K | 2025-09-08 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for Adaptimmune Therapeutics PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Adaptimmune Therapeutics PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34721/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34721 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34721 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34721 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34721}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Adaptimmune Therapeutics PLC (id: 34721)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.